Literature DB >> 14974865

HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands.

Lily H P Nguyen1, Martin J Black, Michael Hier, Peter Chauvin, Louise Rochon.   

Abstract

INTRODUCTION: Mucoepidermoid carcinoma is the most common salivary gland malignancy, representing up to 30% of all cases. Despite attempts to correlate histopathologic grades to clinical outcomes, some histologically "low"-grade lesions continue to behave aggressively despite appropriate treatment.
OBJECTIVE: This preliminary study will attempt to evaluate the use of immunohistochemical markers HER2/neu and Ki-67 as prognostic markers of biologic aggressiveness for mucoepidermoid carcinoma of the salivary glands. DESIGN AND METHODS: A retrospective chart review of 42 patients with mucoepidermoid carcinoma of major and minor salivary glands treated between 1970 and 1995 was conducted. A combination of primary resection with or without postoperative irradiation was used. Histologic grading and correlation with outcome analyses are provided.
RESULTS: In the current study, positive HER2/neu staining and strong Ki-67 staining occurred in patients with high-grade mucoepidermoid carcinoma, whereas low-grade carcinoma was correlated with negative or weak staining.
CONCLUSION: These preliminary results indicate that, overall, the overexpression of both the HER2/neu and the Ki-67 oncoproteins may serve as prognostic markers for poor outcome in salivary gland mucoepidermoid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14974865     DOI: 10.2310/7070.2003.11438

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  15 in total

1.  The Role of Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Mucoepidermoid Carcinomas.

Authors:  Shirin Saravani
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Salivary gland cancers: biology and molecular targets for therapy.

Authors:  Diana Bell; Ehab Y Hanna
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 3.  Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature.

Authors:  Abdullah Mislat Alotaibi; Mohammed Ali Alqarni; Abdelrahman Alnobi; Bassel Tarakji
Journal:  J Clin Diagn Res       Date:  2015-02-01

4.  Expression of Topoisomerase II-α protein in salivary gland tumors.

Authors:  Asaf Shvero; Ohad Hilly; Golan Bubis; Yaniv Hamzany; Rumelia Koren; Lea Rath-Wolfson
Journal:  Mol Clin Oncol       Date:  2017-10-20

5.  Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy.

Authors:  Guanglin Liu; Haiqing Zheng; Zhibing Zhang; Zhiqiang Wu; Huaping Xiong; Jun Li; Libing Song
Journal:  BMC Cancer       Date:  2010-09-16       Impact factor: 4.430

Review 6.  New agents in the treatment for malignancies of the salivary and thyroid glands.

Authors:  Ranee Mehra; Roger B Cohen
Journal:  Hematol Oncol Clin North Am       Date:  2008-12       Impact factor: 3.722

7.  Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.

Authors:  Ryuichi Murase; Tomoki Sumida; Akiko Ishikawa; Rumi Murase; Sean D McAllister; Hiroyuki Hamakawa; Pierre-Yves Desprez
Journal:  Int J Otolaryngol       Date:  2011-11-21

Review 8.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

9.  Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.

Authors:  Shin-ichiro Maruya; Takashi Shirasaki; Takahiko Nagaki; Seiji Kakehata; Hidekachi Kurotaki; Hiroki Mizukami; Hideichi Shinkawa
Journal:  BMC Cancer       Date:  2009-02-27       Impact factor: 4.430

10.  Primary Pulmonary Mucoepidermoid Carcinoma: Histopathological and Moleculargenetic Studies of 26 Cases.

Authors:  Zhen Huo; Huanwen Wu; Ji Li; Shanqing Li; Shafei Wu; Yuanyuan Liu; Yufeng Luo; Jinling Cao; Xuan Zeng; Zhiyong Liang
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.